Celgene Given New $100.00 Price Target at RBC Capital (CELG)
Stock analysts at RBC Capital raised their price target on shares of Celgene (NASDAQ:CELG) from $95.00 to $100.00 in a report issued on Wednesday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price target points to a potential upside of 16.10% from the company’s current price.
CELG has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Monday, July 28th. They now have a $92.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Celgene in a research note on Friday, July 25th. They now have a $95.00 price target on the stock, up previously from $85.00. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Celgene in a research note on Friday, July 25th. They now have a $113.00 price target on the stock, up previously from $112.50. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $96.90.
In other Celgene news, Insider Perry A. Karsen unloaded 39,104 shares of Celgene stock on the open market in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $87.55, for a total value of $3,423,555.20. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Celgene (NASDAQ:CELG) traded down 0.51% during mid-day trading on Wednesday, hitting $86.13. 2,713,557 shares of the company’s stock traded hands. Celgene has a 52 week low of $65.76 and a 52 week high of $90.50. The stock has a 50-day moving average of $86.5 and a 200-day moving average of $78.89. The company has a market cap of $68.862 billion and a price-to-earnings ratio of 50.04.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, July 24th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.01. The company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 17.1% on a year-over-year basis. Analysts expect that Celgene will post $3.68 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Receive News & Ratings for Celgene Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co and related companies with Analyst Ratings Network's FREE daily email newsletter.